Skip to Content

What is the difference between Biktarvy and Descovy?

Medically reviewed by Drugs.com Last updated on Oct 7, 2019.

Official Answer

by Drugs.com

The difference between Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide, or BIC/FTC/TAF) and Descovy (emtricitabine/tenofovir alafenamide, or FTC/TAF) is that Biktarvy contains an extra active ingredient called bictegravir.

Bictegravir is classified as an integrase strand transfer inhibitor and works by blocking the action of integrase, a human immunodeficiency virus (HIV) enzyme that promotes viral replication. Emtricitabine and tenofovir alafenamide are nucleoside reverse transcriptase inhibitors (NRTIs) that block the action of reverse transcriptase, an enzyme that promotes the formation of DNA from RNA.

  Biktarvy Descovy
FDA Approved February 7, 2018 April 4, 2016
How Supplied Each tablet contains:
  • bictegravir 50 mg
  • emtricitabine 200 mg
  • tenofovir alafenamide 25 mg
Each tablet contains:
  • emtricitabine 200 mg
  • tenofovir alafenamide 25 mg
Indications HIV-1 Treatment
  • adults and pediatric patients weighing at least 25 kg
  • used as a complete regimen
HIV-1 Treatment
  • adults and pediatric patients weighing at least 25 kg
  • used in combination with other antiretroviral agents

HIV-1 Pre-Exposure Prophylaxis (PrEP)

  • at-risk HIV-negative men and transgender women weighing at least 35 kg

 

Biktarvy and Descovy are both manufactured by Gilead Sciences Inc.

Related Medical Questions

Drug Information

Related Support Groups

Hide